The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Online Program Home
Abstract Details
|
Activity Number:
|
342
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Tuesday, July 31, 2012 : 10:30 AM to 12:20 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #305684 |
|
Title:
|
Optimal Dose finding for Phase I Cancer Clinical Trials
|
|
Author(s):
|
Shanhong Guan*+
|
|
Companies:
|
Sanofi
|
|
Address:
|
300 Third Street, Cambridge, MA, 02142, United States
|
|
Keywords:
|
Bayesian ;
Clinical trials ;
Dose finding ;
Frequentist ;
Oncology ;
Phase I
|
|
Abstract:
|
The main purpose of a phase I trial of a new antitumor agent is to determine the appropriate dosing regimen and characterize the safety profile of a new anti-cancer treatment. In this paper, commonly used and more recently developed statistical designs, based on either frequentist approaches or Bayesian framework, for phase I cancer clinical trials are reviewed and discussed. Simulation studies are conducted to compare some of the novel designs against traditional approaches such as 3 + 3. Based on empirical numerical results, further discussion on advantages and shortcomings of these designs are provided and directions of designing more efficient phase I cancer trials are explored
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2012 program
|
2012 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.